Table 1

Comparison of all randomised, and survivors assessed at 2 years of age: characteristics at trial entry and etamsylate use

		All randomised				Assessed
		Etamsylate (n=165)	Control (n=169)			Etamsylate (n=101)	Control (n=103)
Country:
France	90	91		52	54
Greece	75	78		49	49
Age at randomisation (min):
<60	18	21		10	13
60–119	55	46		32	24
⩾120	91	101		59	65
Gestational age: <29 weeks	31	35		17	14
Birth weight: <1500 g	114	118		62	70
Sex: male	84	91		50	56
Plurality: multiples	37	38		26	25
No with PIVH	57	62		32	30
No with cerebral problem on scan	57	61		33	31
No with major cerebral problem on scan	21	21		13	8
Fetal presentation: cephalic	98	115		60	72
Mode of delivery: vaginal	88	80		52	49
Steroids	31	22		21	14
Etamsylate doses:
0	4	168		1	102
1–15	25	0		3	0
16	136	1		97	1